Your browser is no longer supported. Please, upgrade your browser.
IRWD Ironwood Pharmaceuticals, Inc. daily Stock Chart
IRWD [NASD]
Ironwood Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.03 Insider Own0.40% Shs Outstand154.73M Perf Week2.48%
Market Cap1.98B Forward P/E20.37 EPS next Y0.63 Insider Trans-28.17% Shs Float152.77M Perf Month12.44%
Income-4.40M PEG- EPS next Q0.23 Inst Own- Short Float17.65% Perf Quarter32.54%
Sales432.80M P/S4.57 EPS this Y-135.70% Inst Trans9.20% Short Ratio17.31 Perf Half Y20.21%
Book/sh-0.98 P/B- EPS next Y25.10% ROA-12.40% Target Price14.13 Perf Year35.58%
Cash/sh- P/C- EPS next 5Y- ROE20.80% 52W Range7.59 - 13.00 Perf YTD47.49%
Dividend- P/FCF- EPS past 5Y4.70% ROI-109.80% 52W High-1.62% Beta1.88
Dividend %- Quick Ratio4.80 Sales past 5Y72.20% Gross Margin92.10% 52W Low68.47% ATR0.35
Employees515 Current Ratio4.90 Sales Q/Q99.70% Oper. Margin10.50% RSI (14)77.06 Volatility2.88% 2.95%
OptionableYes Debt/Eq- EPS Q/Q113.30% Profit Margin-9.70% Rel Volume0.80 Prev Close12.62
ShortableYes LT Debt/Eq- EarningsOct 31 BMO Payout- Avg Volume1.56M Price12.79
Recom2.50 SMA206.10% SMA5021.09% SMA20021.12% Volume1,244,165 Change1.35%
Jul-10-19Resumed Credit Suisse Neutral
Mar-27-19Upgrade Morgan Stanley Underweight → Equal-Weight
Feb-25-19Upgrade H.C. Wainwright Sell → Neutral $14
Jan-24-19Upgrade JP Morgan Underweight → Neutral
Nov-07-18Downgrade JP Morgan Neutral → Underweight
Nov-07-18Downgrade Credit Suisse Outperform → Neutral
Jul-23-18Initiated H.C. Wainwright Sell $12.50
May-09-18Downgrade Morgan Stanley Equal-Weight → Underweight
Jan-05-18Downgrade BofA/Merrill Buy → Underperform
Dec-06-17Downgrade Mizuho Buy → Neutral $16
Jul-21-17Downgrade JP Morgan Overweight → Neutral
May-03-17Initiated Wells Fargo Outperform
Apr-07-17Reiterated Mizuho Buy $21 → $22
Feb-22-17Reiterated Barclays Equal Weight $13 → $16
Nov-04-16Reiterated Mizuho Buy $19 → $20
Oct-24-16Reiterated Wedbush Neutral $10 → $13
Oct-10-16Reiterated Mizuho Buy $24 → $19
Sep-27-16Reiterated WallachBeth Hold $15 → $17
Jul-15-16Reiterated Mizuho Buy $16 → $24
May-10-16Reiterated Mizuho Buy $15 → $16
Dec-13-19 08:39AM  Assertio to Divest Shingles Pain Drug to Alvogen for $127.5M Zacks
Dec-10-19 09:15AM  Some Ironwood Pharmaceuticals (NASDAQ:IRWD) Shareholders Are Down 21% Simply Wall St.
08:33AM  Turning Point (TPTX) Catches Eye: Stock Jumps 6.1% Zacks
Dec-09-19 10:20AM  Sage Therapeutics (SAGE) in Focus: Stock Moves 7.1% Higher Zacks
Dec-03-19 08:51AM  Top Ranked Momentum Stocks to Buy for December 3rd Zacks
Nov-29-19 09:39AM  Catalyst Focuses on Firdapse Label Expansion Amid Competition Zacks
Nov-27-19 08:21AM  The Zacks Analyst Blog Highlights: DexCom, Forterra, NeoPhotonics, Ironwood and Cardtronics Zacks
Nov-26-19 09:36AM  5 Best-Performing, Top-Ranked Growth Stocks of November Zacks
Nov-22-19 09:48AM  The Zacks Analyst Blog Highlights: Jounce Therapeutics, BioDelivery Sciences International, Ironwood Pharmaceuticals, Osmotica Pharmaceuticals and Select Medical Zacks
Nov-21-19 12:15PM  Healthcare Sector Outperforming: 5 Best ETFs & Stocks QTD Zacks
Nov-19-19 09:13AM  Esperion Therapeutics (ESPR) Catches Eye: Stock Jumps 10% Zacks
Nov-11-19 09:21AM  FibroGen (FGEN) Soars: Stock Adds 9.6% in Session Zacks
Nov-08-19 09:24AM  Ironwood Pharmaceuticals, Inc. (IRWD) Shares March Higher, Can It Continue? Zacks
08:00AM  Pharma Sector Tops in October: Best ETFs & Stocks Zacks
Nov-06-19 02:23PM  Edited Transcript of IRWD earnings conference call or presentation 31-Oct-19 12:30pm GMT Thomson Reuters StreetEvents
10:36AM  Jazz Pharma (JAZZ) Q3 Earnings Beat, Xyrem Drives Sales Zacks
10:20AM  Surging Earnings Estimates Signal Upside for Ironwood (IRWD) Stock Zacks
Nov-05-19 04:05PM  Ironwood Pharmaceuticals to Present at the 28th Annual Credit Suisse Healthcare Conference Business Wire
Nov-01-19 10:52AM  Ironwood (IRWD) Beats on Q3 Earnings & Revenues, Ups '19 View Zacks
Oct-31-19 09:05AM  Ironwood Pharmaceuticals (IRWD) Beats Q3 Earnings and Revenue Estimates Zacks +6.47%
07:00AM  Ironwood Pharmaceuticals Reports Third Quarter 2019 Results; Raises Full Year 2019 Guidance Business Wire
Oct-30-19 08:17AM  Ironwood spinout Cyclerion plans 30 layoffs after drug fails mid-stage trial American City Business Journals
Oct-28-19 10:23AM  Hedge Funds Ditched Ironwood Pharmaceuticals, Inc. (IRWD) At The Right Time Insider Monkey
08:00AM  Ironwood Pharmaceuticals to Highlight New Data at the American College of Gastroenterology 2019 Annual Scientific Meeting Business Wire
Oct-24-19 10:32AM  Ironwood Pharmaceuticals (IRWD) Reports Next Week: Wall Street Expects Earnings Growth Zacks
Oct-17-19 04:05PM  Ironwood Pharmaceuticals to Host Third Quarter 2019 Investor Update Call Business Wire
Oct-11-19 08:14AM  Are Investors Undervaluing Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) By 46%? Simply Wall St.
Sep-19-19 02:31PM  Ironwood Amends Linzess Agreement with AstraZeneca in China Zacks
Sep-18-19 07:39AM  The Daily Biotech Pulse: NewLink Genetics Rallies, Breakthrough Designation For Roche, IGM Biosciences Debuts Benzinga
02:00AM  Ironwood Pharmaceuticals and AstraZeneca Amend LINZESS® (linaclotide) Collaboration in China Business Wire
Sep-13-19 11:08AM  Ardelyx Gets FDA Approval for Ibsrela As IBS-C Treatment Zacks
Sep-10-19 03:18PM  Investors Can Find Big Returns with this First Profit Screen Zacks +6.08%
Sep-04-19 10:31AM  Ardelyx (ARDX) Gains on Tenapanor's Success in Pivotal Study Zacks
Aug-30-19 06:14PM  5 Health Care Stocks in Gurus' Portfolios GuruFocus.com
Aug-28-19 04:05PM  Ironwood Pharmaceuticals to Present at Upcoming September Investor Conferences Business Wire
Aug-27-19 08:05AM  Here's Why Ironwood Pharmaceuticals (NASDAQ:IRWD) Can Afford Some Debt Simply Wall St.
Aug-13-19 04:50PM  Ironwood Pharmaceuticals Announces Full Exercise of Convertible Notes Over-Allotment Business Wire
07:30AM  Ironwood Pharmaceuticals and Alnylam Pharmaceuticals Enter U.S. GI Disease Education and Promotional Agreement for Alnylams Givosiran in Acute Hepatic Porphyria (AHP) Business Wire
07:30AM  Alnylam Pharmaceuticals and Ironwood Pharmaceuticals Enter U.S. GI Disease Education and Promotional Agreement for Alnylams Givosiran in Acute Hepatic Porphyria (AHP) Business Wire
Aug-08-19 07:30AM  Ironwood Pharmaceuticals Announces Pricing of Upsized $350 Million Convertible Senior Notes Offering Business Wire
Aug-06-19 04:05PM  Ironwood Pharmaceuticals Announced Proposed Offering of $330 Million of Convertible Senior Notes Business Wire
Aug-03-19 04:45AM  Edited Transcript of IRWD earnings conference call or presentation 30-Jul-19 8:30pm GMT Thomson Reuters StreetEvents
Jul-31-19 10:58AM  Ironwood (IRWD) Q2 Earnings and Revenues Beat Estimates Zacks
06:00AM  Ironwood Pharmaceuticals' Blowout Q2 Results: What You'll Want to Know Motley Fool
04:24AM  Ironwood Pharmaceuticals Inc (IRWD) Q2 2019 Earnings Call Transcript Motley Fool
Jul-30-19 08:45PM  Ironwood Pharmaceuticals (IRWD) Q2 Earnings and Revenues Top Estimates Zacks
04:01PM  Ironwood Pharmaceuticals Reports Second Quarter 2019 Results Business Wire
Jul-23-19 10:32AM  Ironwood Pharmaceuticals (IRWD) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release Zacks
Jul-19-19 12:15PM  Should You Be Concerned About Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Historical Volatility? Simply Wall St.
Jul-18-19 04:05PM  Ironwood Pharmaceuticals to Host Second Quarter 2019 Investor Update Call Business Wire
Jun-21-19 06:09AM  100 Summer lands WeWork ahead of tower's possible sale American City Business Journals
Jun-20-19 07:09PM  Hedge Funds Have Never Been This Bullish On Ironwood Pharmaceuticals, Inc. (IRWD) Insider Monkey
09:40AM  Company News For Jun 20, 2019 Zacks
Jun-19-19 05:21PM  Ironwood's Linzess Lowers Abdominal Symptoms in IBS-C Patients Zacks
10:22AM  Ironwood, Allergan Investors React Positively After Duo's Constipation Drug Found Effective Benzinga
Jun-18-19 04:05PM  Ironwood and Allergan Report Positive Topline Data from Phase IIIb Trial of LINZESS® (linaclotide) in Adults with Irritable Bowel Syndrome with Constipation (IBS-C) Business Wire +8.08%
Jun-13-19 05:14PM  Cambridges Ironwood Pharma moving HQ to downtown Boston American City Business Journals
04:30PM  Ironwood Pharmaceuticals to Establish New Headquarters in Downtown Boston Business Wire
Jun-05-19 09:50AM  Ironwood Initiates Dosing in Mid-Stage Study for MD-7246 Zacks
Jun-03-19 08:30AM  Ironwood Pharmaceuticals and Allergan Initiate Patient Dosing in Phase II Clinical Trial of MD-7246 in Patients with Abdominal Pain Associated with IBS-D Business Wire
Jun-01-19 09:32AM  Why Is Ironwood (IRWD) Up 6.9% Since Last Earnings Report? Zacks
May-24-19 08:00PM  Sarissa Capital Is Drawn to Ironwood Pharmaceuticals Barrons.com
May-17-19 01:58PM  Here's Why Ironwood Pharmaceuticals Rose as Much as 12% Today Motley Fool +13.74%
May-16-19 04:07PM  6 Positions the Vanguard Health Care Fund Continues to Increase GuruFocus.com
04:55AM  Edited Transcript of IRWD earnings conference call or presentation 2-May-19 12:30pm GMT Thomson Reuters StreetEvents
May-09-19 08:00AM  Ironwood Pharmaceuticals to Highlight IW-3718 and Linaclotide Data at Digestive Disease Week® 2019 Business Wire
May-08-19 01:25PM  Did Changing Sentiment Drive Ironwood Pharmaceuticals's (NASDAQ:IRWD) Share Price Down By 41%? Simply Wall St.
May-07-19 04:05PM  Ironwood Pharmaceuticals to Present at the 2019 Bank of America Merrill Lynch Healthcare Conference Business Wire
May-03-19 08:36AM  Ironwood (IRWD) Q1 Earnings & Revenues Miss, Shares Fall Zacks
May-02-19 08:24PM  Ironwood Pharmaceuticals Inc (IRWD) Q1 2019 Earnings Call Transcript Motley Fool -12.82%
12:13PM  Did Hedge Funds Drop The Ball On Ironwood Pharmaceuticals, Inc. (IRWD) ? Insider Monkey
09:35AM  Ironwood Pharmaceuticals (IRWD) Reports Q1 Loss, Misses Revenue Estimates Zacks
08:24AM  Ironwood: 1Q Earnings Snapshot Associated Press
07:00AM  Ironwood Pharmaceuticals Reports First Quarter 2019 Results; Announces Positive 2019 Adjusted EBITDA from Continuing Operations Guidance Business Wire
Apr-25-19 10:34AM  Ironwood Pharmaceuticals (IRWD) Expected to Beat Earnings Estimates: Can the Stock Move Higher? Zacks
Apr-18-19 04:05PM  Ironwood Pharmaceuticals to Host First Quarter 2019 Investor Update Call Business Wire
Apr-16-19 04:02PM  Ironwood Pharmaceuticals Announces Adjustment of Conversion Rate for its 2.25% Convertible Senior Notes due 2020 Business Wire
Apr-05-19 10:34AM  Will Ironwood Suffer From Dependence on Linzess' Progress? Zacks
Apr-02-19 06:23AM  As Ironwood spinout Cyclerion launches on the Nasdaq, CEO Hecht sees 'a fresh start' American City Business Journals
Apr-01-19 04:02PM  Ironwood Pharmaceuticals Completes Separation of Cyclerion Therapeutics and Becomes a Gastrointestinal (GI)-focused Healthcare Company Business Wire
Mar-27-19 02:56PM  Ironwood's new CEO has big plans for Linzess, but is mum on R&D American City Business Journals
Mar-16-19 10:07AM  Read This Before Buying Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Shares Simply Wall St.
Mar-15-19 09:30AM  Why Is Ironwood (IRWD) Down 0.4% Since Last Earnings Report? Zacks
Mar-14-19 04:54PM  Ironwood Announces Effectiveness of Cyclerion Form 10 Registration Statement Business Wire
Mar-07-19 04:05PM  Ironwood Pharmaceuticals to Present at Barclays Global Healthcare Conference Business Wire
Mar-04-19 04:05PM  Ironwood Pharmaceuticals to Present at Cowen Health Care Conference Business Wire
Feb-28-19 08:30AM  Recent Analysis Shows Yamana Gold, Broadcom Inc., Atlas Air Worldwide, Hawaiian, H&E Equipment Services, and Ironwood Pharmaceuticals Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Feb-26-19 09:00AM  Cyclerion, the Planned R&D Spin-off of Ironwood Pharmaceuticals, Secures Commitments of $175 Million in Private Offering Business Wire
Feb-21-19 04:05PM  Ironwood Pharmaceuticals to Present at SVB Leerink Global Healthcare Conference Business Wire
Feb-14-19 10:02AM  Ironwood (IRWD) Q4 Earnings & Revenues Beat, Shares Rise Zacks -5.63%
07:27AM  Edited Transcript of IRWD earnings conference call or presentation 13-Feb-19 1:30pm GMT Thomson Reuters StreetEvents
Feb-13-19 05:17PM  Why Ironwood's Shares Climbed 11.7% on Wednesday Motley Fool +11.66%
03:29PM  Ironwood Pharmaceuticals Inc (IRWD) Q4 2018 Earnings Conference Call Transcript Motley Fool
08:50AM  Ironwood Pharmaceuticals (IRWD) Reports Q4 Loss, Tops Revenue Estimates Zacks
07:52AM  Ironwood: 4Q Earnings Snapshot Associated Press
07:00AM  Ironwood Pharmaceuticals Provides Fourth Quarter and Full Year 2018 Investor Update Business Wire
Feb-10-19 05:37PM  The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials Benzinga
Feb-06-19 10:30AM  Earnings Preview: Ironwood Pharmaceuticals (IRWD) Q4 Earnings Expected to Decline Zacks
Jan-29-19 10:43AM  Allergan (AGN) Q4 Earnings Beat Estimates, 2019 View Tepid Zacks
Jan-28-19 05:00PM  Ironwood Pharmaceuticals to Host Fourth Quarter and Full-Year 2018 Investor Update Call Business Wire
Ironwood Pharmaceuticals, Inc., a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the European Union; MD-7246, an oral, intestinal, non-opioid, pain-relieving agent for patients suffering from IBS with diarrhea; and IW 3718, a gastric retentive formulation of a bile acid sequestrant, which is in Phase III clinical trials for the treatment of GERD. The company pipeline products also include olinciguat, an oral and once-daily vascular sGC stimulator, which is in Phase II trials for the treatment of patients suffering from sickle cell diseases; praliciguat, an oral, once daily systemic sGC stimulator that is in Phase II trials for the treatment of heart failure and for diabetic nephropathy; IW 6463, a central nervous system penetrant oral sGC stimulator in clinical development for serious neurodegenerative diseases; and two organ targeted programs for the treatment of liver and lung. Ironwood Pharmaceuticals, Inc. has collaboration agreements with Allergan plc and AstraZeneca AB to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other gastrointestinal (GI) conditions in North America, China, Hong Kong, Macau, and Japan, as well as a license agreement with Astellas Pharma Inc. to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other GI conditions in Japan. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MacDonald KellyChief Accounting OfficerNov 08Sale11.0098710,85778,337Nov 12 06:26 PM
Consylman GinaSVP, CFO & TreasurerNov 08Sale11.001,51016,610174,138Nov 12 06:23 PM
MCCOURT Thomas APresidentAug 30Option Exercise4.88220,0001,073,600329,739Sep 04 04:42 PM
MCCOURT Thomas APresidentAug 30Sale9.24220,0002,032,800109,739Sep 04 04:42 PM
Consylman GinaSVP, CFO & TreasurerAug 16Sale9.042121,916175,648Aug 20 05:37 PM
Gilbert Halley EChief Admin Officer & SVPJul 26Option Exercise4.8820,00097,600260,169Jul 30 04:48 PM
Gilbert Halley EChief Admin Officer & SVPJul 26Sale10.0020,000200,000240,169Jul 30 04:48 PM
OLANOFF LAWRENCE SDirectorJun 05Sale11.252,00022,50058,259Jun 07 04:06 PM
McHugh JulieDirectorJun 05Sale11.261,50016,890109,337Jun 07 04:05 PM
MCCOURT Thomas APresidentMay 10Sale10.534,05542,699107,239May 14 04:13 PM
Gilbert Halley EChief Admin Officer & SVPMay 10Sale10.534,05542,699238,240May 14 04:12 PM
Currie Mark GDirectorMay 10Sale10.534,05542,699528,903May 14 04:10 PM
Consylman GinaSVP, CFO & TreasurerMay 10Sale10.534,05542,699175,860May 14 04:08 PM
Currie Mark GChief Scientific OfficerMar 08Sale13.1549,500650,925528,480Mar 08 05:51 PM
Currie Mark GChief Scientific OfficerMar 07Sale13.29225,5002,996,895577,980Mar 08 05:51 PM
McHugh JulieDirectorMar 05Sale14.381,50021,57088,131Mar 06 04:07 PM
OLANOFF LAWRENCE SDirectorMar 05Sale14.412,00028,82037,553Mar 06 04:06 PM
MCCOURT Thomas AChief Commercial OfficerFeb 21Sale14.324158783,309Feb 22 04:53 PM
Gilbert Halley EChief Legal OfficerFeb 21Sale14.32851,217225,130Feb 22 04:51 PM
Currie Mark GChief Scientific OfficerFeb 21Sale14.3213186803,480Feb 22 04:49 PM
Consylman GinaChief Financial OfficerFeb 21Sale14.3246659163,184Feb 22 04:47 PM
MCCOURT Thomas AChief Commercial OfficerFeb 20Sale14.314,80068,68883,350Feb 22 04:53 PM
Gilbert Halley EChief Legal OfficerFeb 20Sale14.3110,157145,347225,215Feb 22 04:51 PM
Currie Mark GChief Scientific OfficerFeb 20Sale14.311,63123,340803,493Feb 22 04:49 PM
Consylman GinaChief Financial OfficerFeb 20Sale14.315,63180,580163,230Feb 22 04:47 PM
Gilbert Halley EChief Legal OfficerJan 30Option Exercise4.8920,44999,996235,372Jan 31 05:35 PM
Hecht Peter MChief Executive OfficerJan 25Option Exercise4.8950,000244,5004,726,468Jan 25 06:24 PM
Hecht Peter MChief Executive OfficerJan 25Sale12.2329,551361,4094,696,917Jan 25 06:24 PM
Hecht Peter MChief Executive OfficerJan 24Option Exercise4.8930,000146,7004,726,917Jan 25 06:24 PM
Hecht Peter MChief Executive OfficerJan 24Sale12.7030,000381,0004,696,917Jan 25 06:24 PM
Hecht Peter MChief Executive OfficerJan 23Option Exercise4.8930,000146,7004,726,917Jan 25 06:24 PM
Hecht Peter MChief Executive OfficerJan 23Sale12.6630,000379,8004,696,917Jan 25 06:24 PM